Project Mitigate

Consortium

The MITIGATE consortium combines the expertise of partners from academia groups and SMEs coming from all fields that are necessary to successfully execute the project in a closed loop environment. In the area of rare diseases, personalised healthcare requires a broad field of disciplines for diagnosis and therapy, which are specifically included within the consortium: Particularly the consortium comprises experts in high-field MRI with unique expertise in the fields of X-nuclei MRI and coil development, groups focused on the development of new radiopharmaceuticals for both imaging and therapy as well as groups in the field of minimally-invasive treatment all based on a strong knowledge of molecular oncology coming from academia and industry. The consortium will be supported by a dedicated bioimaging research network organisation.

Consortium_all Logos